Aclaris Therapeutics Stock Price

0.26 (1.23%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aclaris Therapeutics Inc ACRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 1.23% 21.40 19:34:42
Open Price Low Price High Price Close Price Prev Close
21.36 19.8501 21.90 21.31 21.14
Bid Price Ask Price Spread News
21.40 21.50 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,734 605,975 $ 20.85 $ 12,634,156 5,520,502 0.70 - 25.48
Last Trade Time Type Quantity Stock Price Currency
19:34:42 formt 100 $ 21.40 USD

Aclaris Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 963.65M 45.03M 42.99M $ 12.98M $ - -3.90 -13.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Aclaris Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week21.2124.3319.850122.40421,6440.190.9%
1 Month21.5025.4819.5122.13849,190-0.10-0.47%
3 Months3.7325.483.6017.323,307,20817.67473.73%
6 Months2.1025.481.9915.561,733,62919.30919.05%
1 Year1.2025.480.7012.211,122,71420.201,683.33%
3 Years20.3325.480.708.27827,3131.075.26%
5 Years19.6033.250.7010.77585,5571.809.18%

Aclaris Therapeutics Description

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

Your Recent History
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.